TMCnet - World's Largest Communications and Technology Community



Antares Pharma Adds New VP
[March 06, 2008]

Antares Pharma Adds New VP

(Wireless News Via Thomson Dialog NewsEdge)
Antares Pharma announced that Kaushik J. Dave, PhD, RPh, MBA, has
joined the company as Vice President of Clinical and Regulatory Affairs.

Dr. Dave has over 15 years of experience in the pharmaceutical industry
with both large and specialty pharma companies, directing product
development from preclinical to clinical through to commercialization.
His broad experience includes securing multiple product approvals from
the U. S. Food and Drug Administration (FDA), European Medicines Agency
(EMEA) and the Medicines Control Agency (MCA).

Prior to joining Antares Pharma, Dr. Dave was employed by drug delivery
companies Transave and Palatin Technologies, as well as pharmaceutical
companies Schering Plough and Merck, where he was responsible for IND
and NDA submissions for more than 20 products.

He obtained his Pharmacy degree from University of Bath, UK, a PhD in
pharmaceutical chemistry from the University of Kansas, and an MBA from
the Wharton School.

"We are very pleased to have Dr. Dave join our management team at this
juncture; he brings a wealth of clinical and regulatory expertise to
lead our clinical development program. Presently we are enrolling
patients in our pivotal trials for Anturol ATD (Advanced Transdermal
Gel Delivery System) for the treatment of overactive bladder. We are
also initiating a clinical program for our proprietary CNS (ATD gel)
product, AP-1126. Additionally, we are planning a Phase II trial with
the Population Council for our Nestorone/estradiol ATD gel
contraceptive, to commence later this year. The progress of our
clinical program demonstrates our advancement toward becoming a
principal specialty pharma company," said Jack E. Stover, President and

Antares Pharma is a specialized pharma product development company
committed to improving pharmaceuticals through its patented drug
delivery systems. Antares has three validated drug delivery platforms:
the ATDTM Advanced Transdermal Delivery system, subcutaneous injection
technology platforms including both VibexTM disposable mini-needle
injection device and ValeoTM/Vision reusable needle-free injection
devices; and Easy TecTM oral fast-melt technology.

((Comments on this story may be sent to

((Distributed on behalf of 10Meters via M2 Communications Ltd -
((10Meters -

Copyright ? 2008 Wireless News

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy